Epcoritamab

• Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Not authorised
  2023-509861-19-00 Phase II 1 country Universitaet Muenster
• A prospective, open-label, randomized, multicenter phase-III trial to evaluate the efficacy of pirtobrutinib and epcoritamab compared with R… Pending
  2024-513445-37-00 Phase III 4 countries University Of Cologne
• HOVON 178 WM: Treatment of Waldenstrom’s macroglobulinemia with epcoritamab if the disease comes back during or after previous treatment Pending
  2025-522295-91-00 Phase I/II 3 countries Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
• A First-in-Human Trial of DS3790a in Participants with Hematological Malignancies. Pending
  2025-522595-87-00 Phase I (FiH) 2 countries Daiichi Sankyo Inc.
• This study is to find out the safety and effectiveness of Epcoritamab together with R-CHOP (rituximab, cyclophosphamide, doxorubicin HCL, vi… Recruiting
  2023-505277-32-00 Phase III 16 countries AbbVie Deutschland GmbH & Co. KG
• Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Recruiting
  2023-509861-19-01 Phase II 1 country Universitaet Muenster
• Response-adaptive to Epcoritamab In FIrst Relapse: A Phase II, response-adaptive, Open-Label, Multicenter Study to Evaluate the Efficacy of … Recruiting
  2024-514440-86-00 Phase II 1 country Fundacion Geltamo
• A Phase 2 Study evaluating Epcoritamab in subjects with relapsed and refractory primary diffuse large B-cell lymphoma of the CNS treated wit… Recruiting
  2023-505834-84-00 Phase II/III 1 country Lysarc
• HOVON 165 CLL: A prospective randomized phase I/II trial of venetoclax treatment (26 cycles) with 6 cycles or 12 cycles of epcoritamab in pa… Recruiting
  2022-500305-40-00 Phase I/II 4 countries Stichting Hemato-Oncologie voor Volwassenen Nederland (Hovon)
• This study is to evaluate the safety and tolerability of Epcoritamab in Combination with Anti-Neoplastic Agents in Subjects with Non-Hodgkin… Recruiting
  2023-505347-38-00 Phase I/II 7 countries AbbVie Deutschland GmbH & Co. KG
• A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Capsules Compared to Intravenously (IV) Infused Rituximab Plus IV Infu… Ended
  2024-510965-41-00 Phase III 11 countries AbbVie Deutschland GmbH & Co. KG
• Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change i… Ended
  2023-506906-38-00 Phase III 17 countries AbbVie Deutschland GmbH & Co. KG
• EFFICACY AND SAFETY TRIAL OF EPCORITAMAB WITH OR WITHOUT LENALIDOMIDE AS FIRST LINE THERAPY FOR SUBJECTS WITH DIFFUSE LARGE B-CELL LYMPHOMA. Ended
  2023-504832-16-00 Phase II 8 countries Genmab A/S
• This study is to find out about the Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to R2 in… Ended
  2023-505628-67-00 Phase III 14 countries AbbVie Deutschland GmbH & Co. KG
• A Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in R/R DLBCL Ended
  2023-504830-23-00 Phase III 13 countries Genmab A/S
• Safety and Efficacy Study of Epcoritamab in Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome Ended
  2023-504828-25-00 Phase I/II 9 countries Genmab A/S
• Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) Ended
  2023-504805-35-00 Phase I/II 10 countries Genmab A/S
• A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma Ended
  2023-504802-12-00 Phase I (FiH) 9 countries Genmab A/S
• This study is to evaluate the safety and pharmacokinetics of Epcoritamab in Pediatric Patients with Relapsed/ Refractory Aggressive Mature B… Ended
  2023-504795-20-00 Phase I (Other) 6 countries AbbVie Deutschland GmbH & Co. KG

Showing 1–19 of 19 trials